CNOT9
Basic information
Region (hg38): 2:218568580-218597080
Previous symbols: [ "RQCD1" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (1 variants)
- Neurodevelopmental delay (1 variants)
- CNOT9-associated neurodevelopmental disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CNOT9 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 5 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 1 | 3 | 1 | 0 | 0 |
Variants in CNOT9
This is a list of pathogenic ClinVar variants found in the CNOT9 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-218580672-C-G | CNOT9-associated neurodevelopmental disorder | Likely pathogenic (Sep 28, 2022) | ||
2-218580673-G-A | Uncertain significance (Nov 28, 2022) | |||
2-218583025-T-C | Transitional cell carcinoma of the bladder • Gastric adenocarcinoma • Malignant melanoma of skin • Hepatocellular carcinoma • Prostate adenocarcinoma | Likely pathogenic (May 31, 2016) | ||
2-218583026-C-G | Transitional cell carcinoma of the bladder • Prostate adenocarcinoma • Gastric adenocarcinoma • Malignant melanoma of skin • Hepatocellular carcinoma | Likely pathogenic (May 31, 2016) | ||
2-218584682-C-T | Malignant melanoma of skin | Likely pathogenic (May 31, 2016) | ||
2-218584683-C-T | Malignant melanoma of skin • CNOT9-associated neurodevelopmental disorder | Likely pathogenic (Sep 28, 2022) | ||
2-218592371-A-G | Uncertain significance (Feb 12, 2024) | |||
2-218592656-G-A | CNOT9-associated neurodevelopmental disorder | Likely pathogenic (May 04, 2023) | ||
2-218592656-G-C | Uncertain significance (Jun 01, 2023) | |||
2-218594250-C-T | CNOT9-associated neurodevelopmental disorder • Neurodevelopmental delay | Pathogenic (Sep 28, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CNOT9 | protein_coding | protein_coding | ENST00000273064 | 8 | 28501 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.986 | 0.0143 | 125739 | 0 | 2 | 125741 | 0.00000795 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.28 | 48 | 167 | 0.287 | 0.00000916 | 1919 |
Missense in Polyphen | 6 | 64.515 | 0.093001 | 832 | ||
Synonymous | 1.32 | 50 | 63.3 | 0.789 | 0.00000322 | 615 |
Loss of Function | 3.63 | 1 | 17.3 | 0.0579 | 9.60e-7 | 194 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000289 | 0.0000289 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000881 | 0.00000879 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Component of the CCR4-NOT complex which is one of the major cellular mRNA deadenylases and is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation. Additional complex functions may be a consequence of its influence on mRNA expression. Involved in down-regulation of MYB- and JUN-dependent transcription. May play a role in cell differentiation (By similarity). Can bind oligonucleotides, such as poly-G, poly-C or poly-T (in vitro), but the physiological relevance of this is not certain. Does not bind poly-A. Enhances ligand-dependent transcriptional activity of nuclear hormone receptors, including RARA, expect ESR1-mediated transcription that is not only slightly increased, if at all. {ECO:0000250, ECO:0000269|PubMed:17189474, ECO:0000269|PubMed:18180299}.;
- Pathway
- RNA degradation - Homo sapiens (human);miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Gene expression (Transcription);Generic Transcription Pathway;RNA Polymerase II Transcription;Metabolism of RNA;TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain;TP53 Regulates Transcription of Cell Cycle Genes;Transcriptional Regulation by TP53;Deadenylation of mRNA;Deadenylation-dependent mRNA decay
(Consensus)
Recessive Scores
- pRec
- 0.152
Intolerance Scores
- loftool
- rvis_EVS
- -0.12
- rvis_percentile_EVS
- 44.54
Haploinsufficiency Scores
- pHI
- 0.404
- hipred
- Y
- hipred_score
- 0.783
- ghis
- 0.723
Mouse Genome Informatics
- Gene name
- Cnot9
- Phenotype
- homeostasis/metabolism phenotype; embryo phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);
Gene ontology
- Biological process
- nuclear-transcribed mRNA poly(A) tail shortening;DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest;sex differentiation;negative regulation of translation;cytokine-mediated signaling pathway;gene silencing by RNA;positive regulation of peptidyl-serine phosphorylation;negative regulation of intracellular estrogen receptor signaling pathway;positive regulation of epidermal growth factor receptor signaling pathway;positive regulation of nuclear receptor transcription coactivator activity
- Cellular component
- P-body;nucleus;cytosol;membrane;CCR4-NOT complex;CCR4-NOT core complex;protein-containing complex
- Molecular function
- epidermal growth factor receptor binding;protein binding;kinase binding;protein domain specific binding;protein homodimerization activity